{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:26:46Z","timestamp":1790231206677,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Pept Res Ther"],"DOI":"10.1007\/s10989-022-10435-9","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T11:04:56Z","timestamp":1658487896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review"],"prefix":"10.1007","volume":"28","author":[{"given":"Kanchan","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shama","family":"Mujawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-5168","authenticated-orcid":false,"given":"Ashish","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"issue":"5","key":"10435_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jac\/dku570","volume":"70","author":"M Abedinzadeh","year":"2015","unstructured":"Abedinzadeh M, Gaeini M, Sardari S (2015) Natural antimicrobial peptides against Mycobacterium tuberculosis. J Antimicrob Chemothe 70(5):1285\u20131289. https:\/\/doi.org\/10.1093\/jac\/dku570","journal-title":"J Antimicrob Chemothe"},{"key":"10435_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.phrs.2017.10.011","volume":"128","author":"M AlMatar","year":"2018","unstructured":"AlMatar M, Makky EA, Yak\u0131c\u0131 G, Var I, Kayar B, K\u00f6ksal F (2018) Antimicrobial peptides as an alternative to anti-tuberculosis drugs. Pharmacol Res 128:288\u2013305. https:\/\/doi.org\/10.1016\/j.phrs.2017.10.011","journal-title":"Pharmacol Res"},{"key":"10435_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drup.2016.04.002","volume":"26","author":"DI Andersson","year":"2016","unstructured":"Andersson DI, Hughes D, Kubicek-Sutherland JZ (2016) Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updates 26:43\u201357. https:\/\/doi.org\/10.1016\/j.drup.2016.04.002","journal-title":"Drug Resist Updates"},{"key":"10435_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3389\/fimmu.2017.01499","volume":"8","author":"Javier Arranz-Trull\u00e9n","year":"2017","unstructured":"Arranz-Trull\u00e9n, J., Lu, L., Pulido, D., Bhakta, S., & Boix, E\u00a0(2017) Host antimicrobial peptides: The promise of new treatment strategies against tuberculosis. Front\u00a0 Immunol 8:1499 https:\/\/doi.org\/10.3389\/fimmu.2017.01499","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10435_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijmyco.2015.07.002","volume":"5","author":"DI Banerjee","year":"2016","unstructured":"Banerjee DI, Gohil TP (2016) Interaction of antimicrobial peptide with mycolyl transferase in Mycobacterium tuberculosis. Int J Mycobacteriology 5(1):83\u201388. https:\/\/doi.org\/10.1016\/j.ijmyco.2015.07.002","journal-title":"Int J Mycobacteriology"},{"issue":"11","key":"10435_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002375","volume":"7","author":"AW Beham","year":"2011","unstructured":"Beham AW, Puellmann K, Laird R, Fuchs T, Streich R, Breysach C, Raddatz D, Oniga S, Peccerella T, Findeisen P, Kzhyshkowska J, Gratchev A, Schweyer S, Saunders B, Wessels JT, M\u00f6bius W, Keane J, Becker H, Ganser A, Neumaier M, Kaminski WE (2011) A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis. PLoS Pathog 7(11):e1002375. https:\/\/doi.org\/10.1371\/journal.ppat.1002375","journal-title":"PLoS Pathog"},{"issue":"1","key":"10435_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0166-6851(02)00300-6","volume":"127","author":"A Bera","year":"2003","unstructured":"Bera A, Singh S, Nagaraj R, Vaidya T (2003) Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol Biochem Parasitol 127(1):23\u201335. https:\/\/doi.org\/10.1016\/s0166-6851(02)00300-6","journal-title":"Mol Biochem Parasitol"},{"issue":"2","key":"10435_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/oxfordjournals.aje.a120274","volume":"76","author":"T Bjerkedal","year":"1962","unstructured":"Bjerkedal T, Palmer CE (1962) Effect of isoniazid prophylaxis in experimental tuberculosis in guinea pigs. Action of isoniazid in vivo. Am J Hyg 76(2):89\u2013123. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a120274","journal-title":"Am J Hyg"},{"issue":"7","key":"10435_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a017871","volume":"5","author":"J Bruchfeld","year":"2015","unstructured":"Bruchfeld J, Correia-Neves M, Kallenius G (2015) Tuberculosis and HIV coinfection. Cold Spring Harb Perspect Med 5(7):1\u201315. https:\/\/doi.org\/10.1101\/cshperspect.a017871","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10435_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","volume":"10","author":"JA Caminero","year":"2010","unstructured":"Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10(9):621\u2013629. https:\/\/doi.org\/10.1016\/S1473-3099(10)70139-0","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10435_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/QCO.0b013e328319bce6","volume":"21","author":"ED Chan","year":"2008","unstructured":"Chan ED, Iseman MD (2008) Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Curr Opin Infect Dis 21(6):587\u2013595. https:\/\/doi.org\/10.1097\/QCO.0b013e328319bce6","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10435_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10930-013-9530-1","volume":"33","author":"P Chaturvedi","year":"2014","unstructured":"Chaturvedi P, Dhanik M, Pande A (2014) Characterization and structural analysis of hepcidin like antimicrobial peptide from schizothorax richardsonii (Gray). Pro J 33(1):1\u201310. https:\/\/doi.org\/10.1007\/s10930-013-9530-1","journal-title":"Pro J"},{"key":"10435_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9010024","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lu TK (2020) Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics9010024","journal-title":"Antibiotics"},{"issue":"3","key":"10435_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1159\/000490183","volume":"47","author":"X Chen","year":"2018","unstructured":"Chen X, Zou X, Qi G, Tang Y, Guo Y, Si J, Liang L (2018) Roles and mechanisms of human cathelicidin LL-37 in cancer. Cell Physiol Biochem 47(3):1060\u20131073. https:\/\/doi.org\/10.1159\/000490183","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10435_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1021\/cb800240j","volume":"4","author":"A Cherkasov","year":"2009","unstructured":"Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M, Mullaly SC, Volkmer R, Hancock RE (2009) Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 4(1):65\u201374. https:\/\/doi.org\/10.1021\/cb800240j","journal-title":"ACS Chem Biol"},{"key":"10435_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.peptides.2015.07.021","volume":"71","author":"S Chingat\u00e9","year":"2015","unstructured":"Chingat\u00e9 S, Delgado G, Salazar LM, Soto CY (2015) The ATPase activity of the mycobacterial plasma membrane is inhibited by the LL37-analogous peptide LLAP. Peptides 71:222\u2013228. https:\/\/doi.org\/10.1016\/j.peptides.2015.07.021","journal-title":"Peptides"},{"key":"10435_CR17","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e12","author":"C Chung","year":"2020","unstructured":"Chung C, Silwal P, Kim I, Modlin RL, Jo EK (2020) Vitamin D-cathelicidin axis: at the crossroads between protective immunity and pathological inflammation during infection. Immune Netw. https:\/\/doi.org\/10.4110\/in.2020.20.e12","journal-title":"Immune Netw"},{"key":"10435_CR18","unstructured":"Clarke GBM, O'Hea AJ (1961) Chronic pulmonary tuberculosis treatment with ethionamide combined with cycloserine or oxytetracycline.\u00a0Br Med J 1:636\u20138. https:\/\/www.jstor.org\/stable\/20352486"},{"key":"10435_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053162","author":"GD Coxon","year":"2013","unstructured":"Coxon GD, Craig D, Corrales RM, Vialla E, Gannoun-zaki L, Kremer L (2013) Synthesis antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0053162","journal-title":"PLoS ONE"},{"key":"10435_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0041-3879(64)80007-6","volume":"45","author":"J Cuthbert","year":"1964","unstructured":"Cuthbert J, Bruce LG (1964) Treatment of pulmonary tuberculosis by capreomycin and pas: a small preliminary trial. Tubercle 45:205\u2013210. https:\/\/doi.org\/10.1016\/s0041-3879(64)80007-6","journal-title":"Tubercle"},{"issue":"18","key":"10435_CR21","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.3390\/ijms21186741","volume":"21","author":"D Deshpande","year":"2020","unstructured":"Deshpande D, Grieshober M, Wondany F, Gerbl F, Noschka R, Michaelis J, Stenger S (2020) Super-resolution microscopy reveals a direct interaction of intracellular mycobacterium tuberculosis with the antimicrobial peptide LL-37. Int J Mol Sci 21(18):6741. https:\/\/doi.org\/10.3390\/ijms21186741","journal-title":"Int J Mol Sci"},{"issue":"5980","key":"10435_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1185449","volume":"328","author":"C Dye","year":"2010","unstructured":"Dye C, Williams BG (2010) The population dynamics and control of tuberculosis. Science 328(5980):856\u2013861. https:\/\/doi.org\/10.1126\/science.1185449","journal-title":"Science"},{"key":"10435_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/867381","volume-title":"Antimicrobial Peptides Their Role as Infection-Selective Tracers for Molecular Imaging","author":"T Ebenhan","year":"2014","unstructured":"Ebenhan T, Gheysens O, Kruger HG, Zeevaart JR, Sathekge MM (2014) Antimicrobial Peptides Their Role as Infection-Selective Tracers for Molecular Imaging. Internatl, BioMed Res. https:\/\/doi.org\/10.1155\/2014\/867381"},{"issue":"9","key":"10435_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Kasiakou SK (2005) Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333\u20131341. https:\/\/doi.org\/10.1086\/429323","journal-title":"Clin Infect Dis"},{"key":"10435_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050785","author":"A Falanga","year":"2016","unstructured":"Falanga A, Lombardi L, Franci G, Vitiello M, Iovene MR, Morelli G, Galdiero M, Galdiero S (2016) Marine antimicrobial peptides: Nature provides templates for the design of novel compounds against pathogenic bacteria. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms17050785","journal-title":"Int J Mol Sci"},{"key":"10435_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1958.tb54725.x","author":"M Finland","year":"1958","unstructured":"Finland M (1958) Summary of the monograph on the basic and clinical research of the new antibiotic, kanamycin. Ann N Y Acad Sci. https:\/\/doi.org\/10.1111\/j.1749-6632.1958.tb54725.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10435_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd3591","volume":"11","author":"CD Fjell","year":"2012","unstructured":"Fjell CD, Hiss JA, Hancock REW, Schneider G (2012) Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov 11(1):37\u201351. https:\/\/doi.org\/10.1038\/nrd3591","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10435_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nbt.2572","volume":"31","author":"JL Fox","year":"2013","unstructured":"Fox JL (2013) Antimicrobial peptides stage a comeback. Nat Biotechnol 31(5):379\u2013382. https:\/\/doi.org\/10.1038\/nbt.2572","journal-title":"Nat Biotechnol"},{"issue":"10181","key":"10435_CR29","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","volume":"393","author":"J Furin","year":"2019","unstructured":"Furin J, Cox H, Pai M (2019) Tuberculosis. The Lancet 393(10181):1642\u20131656. https:\/\/doi.org\/10.1016\/S0140-6736(19)30308-3","journal-title":"The Lancet"},{"issue":"6","key":"10435_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1067\/mai.2002.129801","volume":"110","author":"RL Gallo","year":"2002","unstructured":"Gallo RL, Murakami M, Ohtake T, Zaiou M (2002) Biology and Clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 110(6):823\u2013831. https:\/\/doi.org\/10.1067\/mai.2002.129801","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10435_CR31","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/jps","volume":"99","author":"O Ghobrial","year":"2010","unstructured":"Ghobrial O, Derendorf H, Hillman JD (2010) Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharma Sci 99(5):2521\u20132528. https:\/\/doi.org\/10.1002\/jps","journal-title":"J Pharma Sci"},{"issue":"3","key":"10435_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1128\/aac.35.3.399","volume":"35","author":"DN Gilbert","year":"1991","unstructured":"Gilbert DN (1991) Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35(3):399\u2013405. https:\/\/doi.org\/10.1128\/aac.35.3.399","journal-title":"Antimicrob Agents Chemother"},{"key":"10435_CR33","unstructured":"Gillespie SH, Kennedy N. (1998) Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 2: 265\u201371. https:\/\/pubmed.ncbi.nlm.nih.gov\/9559396\/"},{"key":"10435_CR34","doi-asserted-by":"publisher","DOI":"10.2478\/s11535-007-0010-5","volume-title":"Antimicrobial peptides: An overview of a promising class of therapeutics","author":"A Giuliani","year":"2007","unstructured":"Giuliani A, Pirri G, Nicoletto SF (2007) Antimicrobial peptides: An overview of a promising class of therapeutics. Eur. J. Biol, Cent. https:\/\/doi.org\/10.2478\/s11535-007-0010-5"},{"issue":"6","key":"10435_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2174\/157489110790112572","volume":"31","author":"F Grumbach","year":"1967","unstructured":"Grumbach F, Rist N (1967) Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV. Rev Tuberc Pneumol 31(6):749\u2013762. https:\/\/doi.org\/10.2174\/157489110790112572","journal-title":"Rev Tuberc Pneumol"},{"issue":"9","key":"10435_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0966-842X(00)01823-0","volume":"8","author":"REW Hancock","year":"2000","unstructured":"Hancock REW, Diamond G (2000) The role of cationic antimicrobial peptides in innate host defences. Trend Microbiol 8(9):402\u2013410. https:\/\/doi.org\/10.1016\/S0966-842X(00)01823-0","journal-title":"Trend Microbiol"},{"key":"10435_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)45122-6","author":"D Heemskerk","year":"2015","unstructured":"Heemskerk D, Caws M, Marais B, Farrar J (2015). Tuberculosis in Children and Adults. https:\/\/doi.org\/10.1016\/S0140-6736(00)45122-6","journal-title":"Tuberculosis in Children and Adults"},{"issue":"5","key":"10435_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0002-9343(47)90087-9","volume":"2","author":"HC Hinshaw","year":"1947","unstructured":"Hinshaw HC, Pyle MM, Feldman WH (1947) Streptomycin in tuberculosis. Am J Med 2(5):429\u2013435. https:\/\/doi.org\/10.1016\/0002-9343(47)90087-9","journal-title":"Am J Med"},{"key":"10435_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2020.582779","volume":"11","author":"Y Huan","year":"2020","unstructured":"Huan Y, Kong Q, Mou H, Yi H (2020) Antimicrobial peptides: classification, design, application and research progress in multiple fields. Front Microbiol 11:1\u201321. https:\/\/doi.org\/10.3389\/fmicb.2020.582779","journal-title":"Front Microbiol"},{"issue":"3","key":"10435_CR40","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/CMR.00056-05","volume":"19","author":"H Jenssen","year":"2006","unstructured":"Jenssen H, Hamill P, Hancock REW (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19(3):491\u2013511. https:\/\/doi.org\/10.1128\/CMR.00056-05","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10435_CR41","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1128\/AAC.01667-10","volume":"55","author":"R Kapoor","year":"2011","unstructured":"Kapoor R, Eimerman PR, Hardy JW, Cirillo JD, Contag CH, Barron AE (2011) Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob Agents Chemother 55(6):3058\u20133062. https:\/\/doi.org\/10.1128\/AAC.01667-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10435_CR42","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/jac\/dkw107","volume":"71","author":"JS Khara","year":"2016","unstructured":"Khara JS, Priestman M, Uh\u00eda I, Hamilton MS, Krishnan N, Wang Y, Yang YY, Langford PR, Newton SM, Robertson BD, Ee PLR (2016) Unnatural amino acid analogues of membrane-active helical peptides with anti-mycobacterial activity and improved stability. J Antimicrob Chemother 71(8):2181\u20132191. https:\/\/doi.org\/10.1093\/jac\/dkw107","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10435_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/13543776.2016.1176149","volume":"26","author":"P Kosikowska","year":"2016","unstructured":"Kosikowska P, Lesner A (2016) Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003\u20132015). Expert Opin Ther Pat 26(6):689\u2013702. https:\/\/doi.org\/10.1080\/13543776.2016.1176149","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10435_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.idc.2016.02.010","volume":"30","author":"SG Kurz","year":"2016","unstructured":"Kurz SG, Furin JJ, Bark CM (2016) Drug-Resistant Tuberculosis: Challenges and Progress. Infect Dis Clin North Am 30(2):509\u2013522. https:\/\/doi.org\/10.1016\/j.idc.2016.02.010","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"10435_CR45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.it.2008.12.003","volume":"30","author":"Y Lai","year":"2009","unstructured":"Lai Y, Gallo RL (2009) AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trend Immunol 30(3):131\u2013141. https:\/\/doi.org\/10.1016\/j.it.2008.12.003","journal-title":"Trend Immunol"},{"issue":"6","key":"10435_CR46","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2165\/00003495-199856060-00011","volume":"56","author":"HM Lamb","year":"1998","unstructured":"Lamb HM, Wiseman LR (1998) Pexiganan acetate. Drugs 56(6):1047\u20131052. https:\/\/doi.org\/10.2165\/00003495-199856060-00011","journal-title":"Drugs"},{"issue":"6","key":"10435_CR47","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.tube.2014.08.001","volume":"94","author":"Y Lan","year":"2014","unstructured":"Lan Y, Lam JT, Siu GKH, Yam WC, Mason AJ, Lam JKW (2014) Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis 94(6):678\u2013689. https:\/\/doi.org\/10.1016\/j.tube.2014.08.001","journal-title":"Tuberculosis"},{"issue":"3","key":"10435_CR48","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/CMR.00006-08","volume":"21","author":"D Landman","year":"2008","unstructured":"Landman D, Georgescu C, Martin DA, Quale J (2008) Polymyxins revisited. Clin Microbiol Rev 21(3):449\u2013465. https:\/\/doi.org\/10.1128\/CMR.00006-08","journal-title":"Clin Microbiol Rev"},{"key":"10435_CR49","unstructured":"Lei J, Sun LC, Huang S, Zhu C, Li P, He J, Mackey V, Coy DH, & He QY (2019). The antimicrobial peptides and their potential clinical applications. Am J Transl Res, 11(7): 3919\u20133931. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6684887\/"},{"issue":"1","key":"10435_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4049\/jimmunol.0903856","volume":"185","author":"LP Ling","year":"2010","unstructured":"Ling LP, Flynn JL (2010) Understanding latent tuberculosis: a moving target. J Immunol 185(1):15\u201322. https:\/\/doi.org\/10.4049\/jimmunol.0903856","journal-title":"J Immunol"},{"issue":"12","key":"10435_CR51","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1086\/593185","volume":"47","author":"BA Lipsky","year":"2008","unstructured":"Lipsky BA, Holroyd KJ, Zasloff M (2008) Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: A randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 47(12):1537\u20131545. https:\/\/doi.org\/10.1086\/593185","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10435_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1089\/mdr.2012.0149","volume":"19","author":"YY Llamas-Gonz\u00e1lez","year":"2013","unstructured":"Llamas-Gonz\u00e1lez YY, Pedroza-Rold\u00e1n C, Cort\u00e9s-Serna MB, M\u00e1rquez-Aguirre AL, G\u00e1lvez-Gast\u00e9lum FJ, Flores-Valdez MA (2013) The synthetic cathelicidin HHC-10 inhibits mycobacterium bovis BCG in vitro and in C57BL\/6 mice. Microb Drug Resist 19(2):124\u2013129. https:\/\/doi.org\/10.1089\/mdr.2012.0149","journal-title":"Microb Drug Resist"},{"key":"10435_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068875","author":"H Lofton","year":"2013","unstructured":"Lofton H, Pr\u00e4nting M, Thulin E, Andersson DI (2013) Mechanisms and fitness costs of resistance to antimicrobial Peptides LL-37, CNY100HL and wheat germ histones. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0068875","journal-title":"PLoS ONE"},{"key":"10435_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000386800","volume":"16","author":"M Lucchesi","year":"1970","unstructured":"Lucchesi M (1970) The antimycobacterial activity of capreomycin. Antibiot Chemother 16:27\u201331","journal-title":"Antibiot Chemother"},{"issue":"1","key":"10435_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1568026615666150703121518","volume":"16","author":"M Malmsten","year":"2015","unstructured":"Malmsten M (2015) Interactions of antimicrobial peptides with bacterial membranes and membrane components. Curr Top Med Chem 16(1):16\u201324. https:\/\/doi.org\/10.2174\/1568026615666150703121518","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"10435_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/trstmh\/trw006","volume":"110","author":"J Manjelievskaia","year":"2016","unstructured":"Manjelievskaia J, Erck D, Piracha S, Schrager L (2016) Drug-resistant TB: deadly, costly and in need of a vaccine. Trans R Soc Trop Med Hyg 110(3):186\u2013191. https:\/\/doi.org\/10.1093\/trstmh\/trw006","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10435_CR57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/psc.2708","volume":"21","author":"SC Mansour","year":"2015","unstructured":"Mansour SC, De La Fuente-N\u00fa\u00f1ez C, Hancock REW (2015) Peptide IDR-1018: Modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J Pept Sci 21(5):323\u2013329. https:\/\/doi.org\/10.1002\/psc.2708","journal-title":"J Pept Sci"},{"issue":"8","key":"10435_CR58","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.bbamem.2008.09.013","volume":"1788","author":"K Matsuzaki","year":"2009","unstructured":"Matsuzaki K (2009) Control of cell selectivity of antimicrobial peptides. Biochim Biophys Acta Biomembrane 1788(8):1687\u20131692. https:\/\/doi.org\/10.1016\/j.bbamem.2008.09.013","journal-title":"Biochim Biophys Acta Biomembrane"},{"issue":"1","key":"10435_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1503\/cmaj.051504","volume":"174","author":"S Murray","year":"2006","unstructured":"Murray S (2006) Challenges of Tuberculosis Control. CMAJ 174(1):33\u201334. https:\/\/doi.org\/10.1503\/cmaj.051504","journal-title":"CMAJ"},{"key":"10435_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/828939","author":"P Narasimhan","year":"2013","unstructured":"Narasimhan P, Wood J, Macintyre CR, Mathai D (2013) Risk factors for tuberculosis. Pulm Med. https:\/\/doi.org\/10.1155\/2013\/828939","journal-title":"Pulm Med"},{"issue":"9","key":"10435_CR61","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tibtech.2011.05.001","volume":"29","author":"LT Nguyen","year":"2011","unstructured":"Nguyen LT, Haney EF, Vogel HJ (2011) The expanding scope of antimicrobial peptide structures and their modes of action. Trend Biotechnol 29(9):464\u2013472. https:\/\/doi.org\/10.1016\/j.tibtech.2011.05.001","journal-title":"Trend Biotechnol"},{"issue":"1","key":"10435_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/AAC.03513-14","volume":"59","author":"AC Nilsson","year":"2015","unstructured":"Nilsson AC, Janson H, Wold H, Fugelli A, Andersson K, H\u00e5kang\u00e5rd C, Olsson P, Olsen WM (2015) Ltx-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive staphylococcus aureus. Antimicrob Agents Chemother 59(1):145\u2013151. https:\/\/doi.org\/10.1128\/AAC.03513-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10435_CR63","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antibiotics3030317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino JC, Martin A (2014) Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 3(3):317\u2013340. https:\/\/doi.org\/10.3390\/antibiotics3030317","journal-title":"Antibiotics"},{"key":"10435_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111071","author":"EA Pel\u00e1ez Coyotl","year":"2020","unstructured":"Pel\u00e1ez Coyotl EA, Barrios Palacios J, Muci\u00f1o G, Moreno-Blas D, Costas M, Montiel Montes T, Diener C, Uribe-Carvajal S, Massieu L, Castro-Obreg\u00f3n S, Espinosa OR (2020) Antimicrobial Peptide against Mycobacterium Tuberculosis That Activates Autophagy Is an Effective Treatment for Tuberculosis. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12111071","journal-title":"Pharmaceutics"},{"issue":"7","key":"10435_CR65","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrmicro1441","volume":"4","author":"A Peschel","year":"2006","unstructured":"Peschel A, Sahl HG (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 4(7):529\u2013536. https:\/\/doi.org\/10.1038\/nrmicro1441","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10435_CR66","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.peptides.2012.05.014","volume":"36","author":"F Pinheiro Da Silva","year":"2012","unstructured":"Pinheiro Da Silva F, MacHado MCC (2012) Antimicrobial peptides: Clinical relevance and therapeutic implications. Peptides 36(2):308\u2013314. https:\/\/doi.org\/10.1016\/j.peptides.2012.05.014","journal-title":"Peptides"},{"issue":"2","key":"10435_CR67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1099\/jmm.0.000912","volume":"68","author":"E Portell-Buj","year":"2019","unstructured":"Portell-Buj E, Vergara A, Alejo I, L\u00f3pez-Gav\u00edn A, Rosa Mont\u00e8 M, San Nicol\u00e0s L, Gonz\u00e0lez-Mart\u00edn J, Tud\u00f3 G (2019) In vitro activity of 12 antimicrobial peptides against mycobacterium tuberculosis and mycobacterium avium clinical isolates. J Med Microbiol 68(2):211\u2013215. https:\/\/doi.org\/10.1099\/jmm.0.000912","journal-title":"J Med Microbiol"},{"issue":"8","key":"10435_CR68","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1128\/AAC.00205-08","volume":"52","author":"M Pr\u00e4nting","year":"2008","unstructured":"Pr\u00e4nting M, Negrea A, Rhen M, Andersson DI (2008) Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar typhimurium LT2. Antimicrob Agents Chemother 52(8):2734\u20132741. https:\/\/doi.org\/10.1128\/AAC.00205-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10435_CR69","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1128\/AAC.00428-13","volume":"57","author":"D Pulido","year":"2013","unstructured":"Pulido D, Torrent M, Andreu D, Nogues MV, Boix E (2013) Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (RNase 3) and RNase 7. Antimicrob Agents Chemother 57(8):3797\u20133805. https:\/\/doi.org\/10.1128\/AAC.00428-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10435_CR70","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1128\/AAC.00175-13","volume":"57","author":"S Ram\u00f3n-Garc\u00eda","year":"2013","unstructured":"Ram\u00f3n-Garc\u00eda S, Mikut R, Ng C, Ruden S, Volkmer R, Reischl M, Hilpert K, Thompson CJ (2013) Targeting mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 57(5):2295\u20132303. https:\/\/doi.org\/10.1128\/AAC.00175-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10435_CR71","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.21037\/jtd.2016.10.14","volume":"8","author":"A Rendon","year":"2016","unstructured":"Rendon A, Tiberi S, Scardigli A, D\u2019Ambrosio L, Centis R, Caminero JA, Migliori GB (2016) Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB) Evidence and perspectives. J Thorac Dis 8(10):2666\u20132671. https:\/\/doi.org\/10.21037\/jtd.2016.10.14","journal-title":"J Thorac Dis"},{"key":"10435_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059119","author":"B Rivas-Santiago","year":"2013","unstructured":"Rivas-Santiago B, Casta\u00f1eda-Delgado JE, Rivas Santiago CE, Waldbrook M, Gonz\u00e1lez-Curiel I, Le\u00f3n-Contreras JC, Enciso-Moreno JA, Villar V.del, Mendez-Ramos, J, Hancock, REW, & Hernandez-Pando R, (2013a) Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against mycobacterium tuberculosis infections in animal models. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0059119","journal-title":"PLoS ONE"},{"issue":"2","key":"10435_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijantimicag.2012.09.015","volume":"41","author":"B Rivas-Santiago","year":"2013","unstructured":"Rivas-Santiago B, Rivas Santiago CE, Casta\u00f1eda-Delgado JE, Le\u00f3n-Contreras JC, Hancock REW, Hernandez-Pando R (2013b) Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 41(2):143\u2013148. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.09.015","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10435_CR74","doi-asserted-by":"publisher","first-page":"101742","DOI":"10.1371\/journal.pone.0101742","volume":"9","author":"A Rodr\u00edguez","year":"2014","unstructured":"Rodr\u00edguez A, Villegas E, Montoya-Rosales A, Rivas-Santiago B, Corzo G (2014) Characterization of antibacterial and hemolytic activity of synthetic pandinin 2 variants and their inhibition against Mycobacterium tuberculosis. PLoS ONE 9(7):101742. https:\/\/doi.org\/10.1371\/journal.pone.0101742","journal-title":"PLoS ONE"},{"key":"10435_CR75","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1128\/IAI.69.5.3248-3254.2001","volume":"69","author":"KF Ross","year":"2001","unstructured":"Ross KF, Herzberg MC (2001) Calprotectin expression by gingival epithelial cells. Infect Immun 69:3248\u20133254. https:\/\/doi.org\/10.1128\/IAI.69.5.3248-3254.2001","journal-title":"Infect Immun"},{"issue":"1","key":"10435_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.peptides.2012.04.018","volume":"36","author":"P Santos","year":"2012","unstructured":"Santos P, Gordillo A, Osses L, Salazar LM, Soto CY (2012) Effect of antimicrobial peptides on ATPase activity and proton pumping in plasma membrane vesicles obtained from mycobacteria. Peptides 36(1):121\u2013128. https:\/\/doi.org\/10.1016\/j.peptides.2012.04.018","journal-title":"Peptides"},{"issue":"7","key":"10435_CR77","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1164\/rccm.201308-1446ED","volume":"188","author":"NW Schluger","year":"2013","unstructured":"Schluger NW (2013) Fluoroquinolones in The treatment of tuberculosis: Which is best? Am J Respir Crit Care Med 188(7):768\u2013769. https:\/\/doi.org\/10.1164\/rccm.201308-1446ED","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10435_CR78","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML (2015) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 5(9):a017863","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10435_CR79","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1002\/chem.201404650","volume":"21","author":"A Sharma","year":"2015","unstructured":"Sharma A, Pohane AA, Bansal S, Bajaj A, Jain V, Srivastava A (2015) Cell penetrating synthetic antimicrobial peptides (SAMPs) exhibiting potent and selective killing of Mycobacterium by targeting its DNA. Chem Eur J 21(9):3540\u20133545. https:\/\/doi.org\/10.1002\/chem.201404650","journal-title":"Chem Eur J"},{"issue":"6049","key":"10435_CR80","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1208813","volume":"333","author":"W Shi","year":"2011","unstructured":"Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y (2011) Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333(6049):1630\u20131632. https:\/\/doi.org\/10.1126\/science.1208813","journal-title":"Science"},{"issue":"1","key":"10435_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-74432-y","volume":"10","author":"SS Shivekar","year":"2020","unstructured":"Shivekar SS, Kaliaperumal V, Brammacharry U, Sakkaravarthy A, Raj CKV, Alagappan C, Muthaiah M (2020) Prevalence and factors associated with multidrug-resistant tuberculosis in South India. Sci Rep 10(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-020-74432-y","journal-title":"Sci Rep"},{"issue":"5","key":"10435_CR82","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.biotechadv.2016.05.007","volume":"34","author":"JP Silva","year":"2016","unstructured":"Silva JP, Appelberg R, Gama FM (2016a) Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv 34(5):924\u2013940. https:\/\/doi.org\/10.1016\/j.biotechadv.2016.05.007","journal-title":"Biotechnol Adv"},{"key":"10435_CR83","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jconrel.2016.05.064","volume":"235","author":"JP Silva","year":"2016","unstructured":"Silva JP, Gon\u00e7alves C, Costa C, Sousa J, Silva-Gomes R, Castro AG, Pedrosa J, Appelberg R, Gama FM (2016b) Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment. J Control Release 235:112\u2013124. https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.064","journal-title":"J Control Release"},{"issue":"1","key":"10435_CR84","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/femsre\/fuv008","volume":"40","author":"C Sohlenkamp","year":"2015","unstructured":"Sohlenkamp C, Geiger O (2015) Bacterial membrane lipids: diversity in structures and pathways. FEMS Microbiol Rev 40(1):133\u2013159. https:\/\/doi.org\/10.1093\/femsre\/fuv008","journal-title":"FEMS Microbiol Rev"},{"issue":"4","key":"10435_CR85","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.tube.2011.03.003","volume":"91","author":"FB Sow","year":"2011","unstructured":"Sow FB, Nandakumar S, Velu V, Kellar KL, Schlesinger LS, Amara RR, Lafuse WP, Shinnick TM, Sable SB (2011) Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin. Tuberculosis 91(4):314\u2013321. https:\/\/doi.org\/10.1016\/j.tube.2011.03.003","journal-title":"Tuberculosis"},{"issue":"3","key":"10435_CR86","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1128\/IAI.05987-11","volume":"80","author":"JT Sullivan","year":"2012","unstructured":"Sullivan JT, Young EF, Mccann JR, Braunstein M (2012) The mycobacterium tuberculosis SecA2 system subverts phagosome maturation to promote growth in macrophages. Infect Immun 80(3):996\u20131006. https:\/\/doi.org\/10.1128\/IAI.05987-11","journal-title":"Infect Immun"},{"issue":"2","key":"10435_CR87","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-2249.2003.02063.x","volume":"131","author":"L Szereday","year":"2003","unstructured":"Szereday L, Baliko Z, Szekeres-Bartho J (2003) Gamma\/delta T cell subsets in patients with active Mycobacterium tuberculosis infection and tuberculin anergy. Clin Exp Immunol 131(2):287\u2013291. https:\/\/doi.org\/10.1046\/j.1365-2249.2003.02063.x","journal-title":"Clin Exp Immunol"},{"key":"10435_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/bay025","volume":"2018","author":"SS Usmani","year":"2018","unstructured":"Usmani SS, Kumar R, Kumar V, Singh S, Raghava GPS (2018) AntiTbPdb: A knowledgebase of anti-tubercular peptides. Database 2018:1\u20138. https:\/\/doi.org\/10.1093\/database\/bay025","journal-title":"Database"},{"key":"10435_CR89","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1741-7015-7-44","volume":"7","author":"WJFM Van der Velden","year":"2009","unstructured":"Van der Velden WJFM, van Iersel TMP, Blijlevens NMA, Donnelly JP (2009) Safety and tolerability of the antimicrobial peptide human lactoferrin 1\u201311 (hLF1-11). BMC Med 7:44. https:\/\/doi.org\/10.1186\/1741-7015-7-44","journal-title":"BMC Med"},{"key":"10435_CR90","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3389\/fimmu.2018.03128","volume":"9","author":"JFA Varga","year":"2018","unstructured":"Varga JFA, Bui-Marinos MP, Katzenback BA (2018) Frog skin innate immune defences: sensing and surviving pathogens. Front Immunol 9:3128","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"10435_CR91","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","volume":"15","author":"P Vlieghe","year":"2010","unstructured":"Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discov Today 15(1\u20132):40\u201356. https:\/\/doi.org\/10.1016\/j.drudis.2009.10.009","journal-title":"Drug Discov Today"},{"issue":"5","key":"10435_CR92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4161\/viru.1.5.12983","volume":"1","author":"J Wiesner","year":"2010","unstructured":"Wiesner J, Vilcinskas A (2010) Antimicrobial peptides: The ancient arm of the human immune system. In Virulence 1(5):440\u2013464. https:\/\/doi.org\/10.4161\/viru.1.5.12983","journal-title":"In Virulence"},{"key":"10435_CR93","unstructured":"World Health Organization (2020) Tuberculosis Report. In Baltimore Health News: XLIX (Issues 9\u201310\u201311)"},{"key":"10435_CR94","unstructured":"Yeager R, Munroe W, Dessau F. Pyrazinamide (1952) (Aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc\u00a065,523\u2013534. https:\/\/pubmed.ncbi.nlm.nih.gov\/14924175\/"},{"issue":"13","key":"10435_CR95","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00018-011-0710-x","volume":"68","author":"ATY Yeung","year":"2011","unstructured":"Yeung ATY, Gellatly SL, Hancock REW (2011) Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 68(13):2161\u20132176. https:\/\/doi.org\/10.1007\/s00018-011-0710-x","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10435_CR96","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1128\/aac.35.10.2159","volume":"35","author":"WW Yew","year":"1991","unstructured":"Yew WW, Lee J, Chan CY, Cheung SW, Wong PC, Kwan SY (1991) Ofloxacin penetration into tuberculous pleural effusion. Antimicrob Agents Chemother 35(10):2159\u20132160. https:\/\/doi.org\/10.1128\/aac.35.10.2159","journal-title":"Antimicrob Agents Chemother"},{"key":"10435_CR97","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3138\/9781487589684-006","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389\u2013395. https:\/\/doi.org\/10.3138\/9781487589684-006","journal-title":"Nature"},{"issue":"6","key":"10435_CR98","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/jac\/dkm357","volume":"60","author":"AP Zavascki","year":"2007","unstructured":"Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother 60(6):1206\u20131215. https:\/\/doi.org\/10.1093\/jac\/dkm357","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Peptide Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10989-022-10435-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10989-022-10435-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10989-022-10435-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:13:12Z","timestamp":1744204392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10989-022-10435-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["10435"],"URL":"https:\/\/doi.org\/10.1007\/s10989-022-10435-9","relation":{},"ISSN":["1573-3904"],"issn-type":[{"value":"1573-3904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"16 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"132"}}